Key Takeaways:
GSK and Hansoh Pharmaceutical's experimental drug Ris-Rez kept an aggressive bone cancer from worsening in a Phase 3 trial, the companies said Tuesday.
Ris-Rez showed a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy, Hansoh said in a statement. The drug, an antibody-drug conjugate (ADC) that targets the B7-H3 protein, is designed to deliver cell-killing compounds directly to tumors while largely sparing healthy tissue — a class of therapies often described as "guided missiles."
The results come just weeks after Ris-Rez succeeded in another advanced study on July 10, reinforcing the drug's potential across multiple indications. GSK, which holds rights to the drug outside China, is accelerating development of Ris-Rez alongside Mo-Rez, another ADC licensed from Hansoh that the British drugmaker has described as a potential blockbuster.
The positive readout strengthens GSK's oncology pipeline as the company works to rebuild its cancer portfolio following a series of setbacks in recent years. Osteosarcoma, the indication tested in this trial, is a rare but aggressive bone cancer with limited treatment options for patients whose disease has relapsed after initial therapy.
For GSK shareholders, the data reduces clinical risk on one of the company's most closely watched pipeline assets and validates the partnership with Hansoh, which was structured to give GSK ex-China rights while Hansoh retains the China market. Investors will watch for regulatory filings in the coming months and for additional data readouts from the ongoing development program across other tumor types.
